Infectious Disease Aspects of the Brain-Dead Potential Organ Donor



Organ procurement organizations have the task of evaluating potential deceased organs donors for both active and latent infections in order to protect the potential recipients. We discuss deceased donor evaluation and infectious disease screening, as well as donor-derived infections in organ transplant recipients, both expected and unexpected.


West Nile Virus Organ Donor Transplant Center Deceased Donor Nucleic Acid Testing 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Calabrese F, Angelini A, Cecchetto A, Valente M, Livi U, Thiene G. HIV infection in the first heart transplantation in Italy: fatal outcome. Case report. APMIS. 1998;106(4):470–4.PubMedCrossRefGoogle Scholar
  2. 2.
    Fischer SA, Graham MB, Kuehnert MJ, et al. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med. 2006;354(21):2235–49.PubMedCrossRefGoogle Scholar
  3. 3.
    Iwamoto M, Jernigan DB, Guasch A, et al. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med. 2003;348(22):2196–203.PubMedCrossRefGoogle Scholar
  4. 4.
    HIV transmitted from a living organ donor—New York City, 2009. MMWR Morb Mortal Wkly Rep. 2011;60(10):297–301.Google Scholar
  5. 5.
    Ison MG, Llata E, Conover CS, et al. Transmission of Human Immunodeficiency Virus and Hepatitis C Virus from an organ donor to four transplant recipients. Am J Transplant. 2011;11(6):1218–25.PubMedCrossRefGoogle Scholar
  6. 6.
    Ison MG, Nalesnik MA. An update on donor-derived disease transmission in organ transplantation. Am J Transplant. 2011;11:1123–30.PubMedCrossRefGoogle Scholar
  7. 7.
    OPTN Policy 4.0 Acquired Immune Deficiency syndrome (AIDS), human pituitary derived growth hormone (HPDGH), and reporting of potential recipent diseases or medical conditions, including malignancies, of donor origin.
  8. 8.
    Ison MG, Hager J, Blumberg E, et al. Donor-derived disease transmission events in the United States: data reviewed by the OPTN/UNOS Disease Transmission Advisory Committee. Am J Transplant. 2009;9(8):1929–35.PubMedCrossRefGoogle Scholar
  9. 9.
    2009 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1999–2008. Rockville, MD: U.S. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation.Google Scholar
  10. 10.
    Testing HCT/P donors for relevant communicable disease agents and diseases. Accessed June 11, 2011.
  11. 11.
    Kucirka LM, Sarathy H, Govindan P, et al. Risk of window period Hepatitis-C infection in high infectious risk donors: systematic review and meta-analysis. Am J Transplant. 2011;11(6):1188–200.PubMedCrossRefGoogle Scholar
  12. 12.
    Kucirka LM, Sarathy H, Govindan P, et al. Risk of window period HIV infection in high infectious risk donors: systematic review and meta-analysis. Am J Transplant. 2011;11(6):1176–87.PubMedCrossRefGoogle Scholar
  13. 13.
    Kucirka LM, Singer AL, Segev DL. High infectious risk donors: what are the risks and when are they too high? Curr Opin Organ Transplant. 2011;16(2): 256–61.PubMedCrossRefGoogle Scholar
  14. 14.
    Kaul DR, Taranto S, Alexander C, et al. Donor screening for human T-cell lymphotrophic virus 1/2: changing paradigms for changing testing capacity. Am J Transplant. 2010;10(2):207–13.PubMedCrossRefGoogle Scholar
  15. 15.
    Humar A, Morris M, Blumberg E, et al. Nucleic acid testing (NAT) of organ donors: is the ‘best’ test the right test? A consensus conference report. Am J Transplant. 2010;10(4):889–99.PubMedCrossRefGoogle Scholar
  16. 16.
    Miller R, Covington S, Taranto S, Taylor K, Parker K, Comellas C, Ehsan A, et al., OPTN Ad Hoc Disease Transmission. Communication gaps associated with donor derived infections (DDIs): a report from the OPTN Ad Hoc Diseases Transmission Advisory Committee (DTAC) [Abstract]. American Transplant Congress, Philadelphia, PA, 2011.Google Scholar
  17. 17.
    Transplantation-transmitted tuberculosis—­Oklahoma and Texas, 2007. MMWR Morb Mortal Wkly Rep. 2008;57(13):333–6.Google Scholar
  18. 18.
    Chin-Hong PV, Schwartz BS, Bern C, et al. Screening and treatment of chagas disease in organ transplant recipients in the United States: recommendations from the chagas in transplant working group. Am J Transplant. 2011;11(4):672–80.PubMedCrossRefGoogle Scholar
  19. 19.
    Kotton CN, Lattes R. Parasitic infections in solid organ transplant recipients. Am J Transplant. 2009;9 Suppl 4:S234–251.PubMedCrossRefGoogle Scholar
  20. 20.
    Fischer SA, Avery RK. Screening of donor and recipient prior to solid organ transplantation. Am J Transplant. 2009;9 Suppl 4:S7–18.PubMedCrossRefGoogle Scholar
  21. 21.
    Lopez-Navidad A, Domingo P, Caballero F, Gonzalez C, Santiago C. Successful transplantation of organs retrieved from donors with bacterial meningitis. Transplantation. 1997;64(2):365–8.PubMedCrossRefGoogle Scholar
  22. 22.
    OPTN Policy 2.0 Minimum procurement standards for an organ procurement organization (OPO). Accessed May 18, 2011.
  23. 23.
    Morris MI, Fischer SA, Ison MG. Infections transmitted by transplantation. Infect Dis Clin North Am. 2010;24(2):497–514.PubMedCrossRefGoogle Scholar
  24. 24.
    Update: Investigations of West Nile virus infections in recipients of organ transplantation and blood transfusion. MMWR Morb Mortal Wkly Rep. 2002;51(37): 833–6.Google Scholar
  25. 25.
    West Nile virus infection in organ donor and ­transplant recipients—Georgia and Florida, 2002. MMWR Morb Mortal Wkly Rep. 2002;51(35):790.Google Scholar
  26. 26.
    Update: West Nile virus screening of blood donations and transfusion-associated transmission—United States, 2003. MMWR Morb Mortal Wkly Rep. 2004; 53(13):281–4.Google Scholar
  27. 27.
    West Nile virus infections in organ transplant recipients—New York and Pennsylvania, August-September, 2005. MMWR Morb Mortal Wkly Rep. 2005;54(40):1021–3.Google Scholar
  28. 28.
    West Nile virus transmission through blood transfusion—South Dakota, 2006. MMWR Morb Mortal Wkly Rep. 2007;56(4):76–9.Google Scholar
  29. 29.
    Detection of West Nile virus in blood donations—Puerto Rico, 2007. MMWR Morb Mortal Wkly Rep. 2008;57(21):577–80.Google Scholar
  30. 30.
    Macedo de Oliveira A, Beecham BD, Montgomery SP, et al. West Nile virus blood transfusion-related infection despite nucleic acid testing. Transfusion. 2004;44(12):1695–9.Google Scholar
  31. 31.
    Zhang W, Wu J, Li Y, Li F, Njoo H. Rapid and accurate in vitro assays for detection of West Nile virus in blood and tissues. Transfus Med Rev. 2009;23(2): 146–54.PubMedCrossRefGoogle Scholar
  32. 32.
    Rhee C, Eaton EF, Concepcion W, Blackburn BG. West Nile virus encephalitis acquired via liver transplantation and clinical response to intravenous immunoglobulin: case report and review of the literature. Transpl Infect Dis. 2011;13(3):312–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Morelli MC, Sambri V, Grazi GL, et al. Absence of neuroinvasive disease in a liver transplant recipient who acquired West Nile virus (WNV) infection from the organ donor and who received WNV antibodies prophylactically. Clin Infect Dis. 2010;51(4):e34–37.PubMedCrossRefGoogle Scholar
  34. 34.
    Guidance for Industry: Assessing Donor Suitability and Blood and Blood Product Safety in Cases of Known or Suspected West Nile Virus Infection Accessed May 22, 2011.
  35. 35.
    West Nile virus transmission via organ transplantation and blood transfusion—Louisiana, 2008. MMWR Morb Mortal Wkly Rep. 2009;58(45):1263–7.Google Scholar
  36. 36.
    Tilley PA, Fox JD, Lee B, Chui L, Preiksaitis J. Screening of organ and tissue donors for West Nile virus by nucleic acid amplification—a three year experience in Alberta. Am J Transplant. 2008;8(10): 2119–25.PubMedCrossRefGoogle Scholar
  37. 37.
    Kiberd BA, Forward K. Screening for West Nile virus in organ transplantation: a medical decision analysis. Am J Transplant. 2004;4(8):1296–301.PubMedCrossRefGoogle Scholar
  38. 38.
    Guidelines for preventing transmission of human immunodeficiency virus through transplantation of human tissue and organs. Centers for Disease Control and Prevention. MMWR Recomm Rep. 1994;43(RR-8):1–17.Google Scholar
  39. 39.
    Ahn J, Cohen SM. Transmission of human immunodeficiency virus and hepatitis C virus through liver transplantation. Liver Transpl. 2008;14(11): 1603–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Kucirka LM, Alexander C, Namuyinga R, Hanrahan C, Montgomery RA, Segev DL. Viral nucleic acid testing (NAT) and OPO-level disposition of high-risk donor organs. Am J Transplant. 2009;9(3):620–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products. Accessed June 11, 2011.
  42. 42.
    Humar A, Snydman D. Cytomegalovirus in solid organ transplant recipients. Am J Transplant. 2009;9 Suppl 4:S78–86.PubMedCrossRefGoogle Scholar
  43. 43.
    Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation. 2010;89(7):779–95.PubMedCrossRefGoogle Scholar
  44. 44.
    Allen U, Preiksaitis J. Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients. Am J Transplant. 2009;9 Suppl 4:S87–96.PubMedCrossRefGoogle Scholar
  45. 45.
    Muller E, Kahn D, Mendelson M. Renal transplantation between HIV-positive donors and recipients. N Engl J Med. 2010;362(24):2336–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Singer AL, Kucirka LM, Namuyinga R, Hanrahan C, Subramanian AK, Segev DL. The high-risk donor: viral infections in solid organ transplantation. Curr Opin Organ Transplant. 2008;13(4):400–4.PubMedCrossRefGoogle Scholar
  47. 47.
    Stramer SL, Wend U, Candotti D, et al. Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med. 2011;364(3):236–47.PubMedCrossRefGoogle Scholar
  48. 48.
    Kleinman SH, Busch MP. Assessing the impact of HBV NAT on window period reduction and residual risk. J Clin Virol. 2006;36 Suppl 1:S23–29.PubMedCrossRefGoogle Scholar
  49. 49.
    Mandell GL, Bennett JE, Dolin R. Douglas, Mandell and Bennett’s principles and practice of infectious diseases. 7th ed. Philadelphia: Churchill Livingstone; 2010.Google Scholar
  50. 50.
    Chung RT, Feng S, Delmonico FL. Approach to the management of allograft recipients following the detection of hepatitis B virus in the prospective organ donor. Am J Transplant. 2001;1(2):185–91.PubMedCrossRefGoogle Scholar
  51. 51.
    Jiang H, Wu J, Zhang X, et al. Kidney transplantation from hepatitis B surface antigen positive donors into hepatitis B surface antibody positive recipients: a ­prospective nonrandomized controlled study from a single center. Am J Transplant. 2009;9(8):1853–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Fong TL, Bunnapradist S, Jordan SC, Cho YW. Impact of hepatitis B core antibody status on outcomes of cadaveric renal transplantation: analysis of United network of organ sharing database between 1994 and 1999. Transplantation. 2002;73(1): 85–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Levitsky J, Doucette K. Viral hepatitis in solid organ transplant recipients. Am J Transplant. 2009;9 Suppl 4:S116–130.PubMedCrossRefGoogle Scholar
  54. 54.
    Ouseph R, Eng M, Ravindra K, Brock GN, Buell JF, Marvin MR. Review of the use of hepatitis B core antibody-positive kidney donors. Transplant Rev (Orlando). 2010;24(4):167–71.CrossRefGoogle Scholar
  55. 55.
    Fishman JA, Rubin RH, Koziel MJ, Periera BJ. Hepatitis C virus and organ transplantation. Transplantation. 1996;62(2):147–54.PubMedCrossRefGoogle Scholar
  56. 56.
    Pereira BJ, Natov SN, Bouthot BA, et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int. 1998;53(5):1374–81.PubMedCrossRefGoogle Scholar
  57. 57.
    Abbott KC, Bucci JR, Matsumoto CS, et al. Hepatitis C and renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol. 2003;14(11): 2908–18.PubMedCrossRefGoogle Scholar
  58. 58.
    Abbott KC, Lentine KL, Bucci JR, Agodoa LY, Peters TG, Schnitzler MA. The impact of transplantation with deceased donor hepatitis c-positive kidneys on survival in wait-listed long-term dialysis patients. Am J Transplant. 2004;4(12):2032–7.PubMedCrossRefGoogle Scholar
  59. 59.
    Cotler SJ, Jensen DM, Kesten S. Hepatitis C virus infection and lung transplantation: a survey of practices. J Heart Lung Transplant. 1999;18(5):456–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Lake KD, Smith CI, LaForest SK, Allen J, Pritzker MR, Emery RW. Policies regarding the transplantation of hepatitis C-positive candidates and donor organs. J Heart Lung Transplant. 1997;16(9):917–21.PubMedGoogle Scholar
  61. 61.
    Taylor RM, Pietroski RE, Hagan M, Eisenbrey AB, Fontana RJ. Seropositive abdominal and thoracic donor organs are largely underutilized. Transplant Proc. 2010;42(10):4479–87.PubMedCrossRefGoogle Scholar
  62. 62.
    Ballarin R, Cucchetti A, Spaggiari M, et al. Long-term follow-up and outcome of liver transplantation from Anti-Hepatitis C virus-positive donors: a European multicentric case-control study. Transplantation. 2011;91(11):1265–72.PubMedCrossRefGoogle Scholar
  63. 63.
    Kasprzyk T, Kwiatkowski A, Wszola M, et al. Long-term results of kidney transplantation from HCV-positive donors. Transplant Proc. 2007;39(9):2701–3.PubMedCrossRefGoogle Scholar
  64. 64.
    Kucirka LM, Singer AL, Ros RL, Montgomery RA, Dagher NN, Segev DL. Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients. Am J Transplant. 2010;10(5):1238–46.PubMedCrossRefGoogle Scholar
  65. 65.
    Freeman RB, Giatras I, Falagas ME, et al. Outcome of transplantation of organs procured from bacteremic donors. Transplantation. 1999;68(8):1107–11.PubMedCrossRefGoogle Scholar
  66. 66.
    Cerutti E, Stratta C, Romagnoli R, et al. Bacterial- and fungal-positive cultures in organ donors: clinical impact in liver transplantation. Liver Transpl. 2006; 12(8):1253–9.PubMedCrossRefGoogle Scholar
  67. 67.
    Kumar D, Cattral MS, Robicsek A, Gaudreau C, Humar A. Outbreak of pseudomonas aeruginosa by multiple organ transplantation from a common donor. Transplantation. 2003;75(7):1053–5.PubMedCrossRefGoogle Scholar
  68. 68.
    Meylan PR, Aubert JD, Kaiser L. Influenza transmission to recipient through lung transplantation. Transpl Infect Dis. 2007;9(1):55–7.PubMedCrossRefGoogle Scholar
  69. 69.
    Le Page AK, Kainer G, Glanville AR, Tu E, Bhonagiri D, Rawlinson WD. Influenza B virus transmission in recipients of kidney and lung transplants from an infected donor. Transplantation. 2010;90(1):99–102.PubMedCrossRefGoogle Scholar
  70. 70.
    Kumar D, Morris MI, Kotton CN, et al. Guidance on novel influenza A/H1N1 in solid organ transplant recipients. Am J Transplant. 2010;10(1):18–25.PubMedCrossRefGoogle Scholar
  71. 71.
    Palacios G, Druce J, Du L, et al. A new arenavirus in a cluster of fatal transplant-associated diseases. N Engl J Med. 2008;358(10):991–8.PubMedCrossRefGoogle Scholar
  72. 72.
    Kumar D, Humar A. Emerging viral infections in transplant recipients. Curr Opin Infect Dis. 2005; 18(4):337–41.PubMedCrossRefGoogle Scholar
  73. 73.
    Lumbreras C, Sanz F, Gonzalez A, et al. Clinical significance of donor-unrecognized bacteremia in the outcome of solid-organ transplant recipients. Clin Infect Dis. 2001;33(5):722–6.PubMedCrossRefGoogle Scholar
  74. 74.
    Patel G, Perez F, Bonomo RA. Carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii: assessing their impact on organ transplantation. Curr Opin Organ Transplant. 2010;15:676–682.Google Scholar
  75. 75.
    Transmission of multidrug-resistant Escherichia coli through kidney transplantation—California and Texas, 2009. MMWR Morb Mortal Wkly Rep. 2010;59(50):1642–6.Google Scholar
  76. 76.
    Mrzljak A, Peric Z, Kovacevic V, Gustin D, Vrhovac R, Andrasevic AT. Rising problem of multidrug-resistant gram-negative bacteria causing bloodstream infections after liver transplantation: how should we handle the issue? Liver Transpl. 2010;16(10): 1217–9.PubMedCrossRefGoogle Scholar
  77. 77.
    Bert F, Larroque B, Paugam-Burtz C, et al. Microbial epidemiology and outcome of bloodstream infections in liver transplant recipients: an analysis of 259 episodes. Liver Transpl. 2010;16(3):393–401.PubMedGoogle Scholar
  78. 78.
    Nelson PW, Delmonico FL, Tolkoff-Rubin NE, et al. Unsuspected donor pseudomonas infection causing arterial disruption after renal transplantation. Transplantation. 1984;37(3):313–4.PubMedCrossRefGoogle Scholar
  79. 79.
    Calvino J, Romero R, Pintos E, et al. Renal artery rupture secondary to pretransplantation Candida contamination of the graft in two different recipients. Am J Kidney Dis. 1999;33(1):E3.PubMedCrossRefGoogle Scholar
  80. 80.
    Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis. 1998;27(5):1266–77.PubMedCrossRefGoogle Scholar
  81. 81.
    Limaye AP, Connolly PA, Sagar M, et al. Transmission of Histoplasma capsulatum by organ transplantation. N Engl J Med. 2000;343(16):1163–6.PubMedCrossRefGoogle Scholar
  82. 82.
    Tripathy U, Yung GL, Kriett JM, Thistlethwaite PA, Kapelanski DP, Jamieson SW. Donor transfer of ­pulmonary coccidioidomycosis in lung transplantation. Ann Thorac Surg. 2002;73(1):306–8.PubMedCrossRefGoogle Scholar
  83. 83.
    Shah SS, Karnak D, Shah SN, et al. Broncholith caused by donor-acquired histoplasmosis in a lung transplant recipient. J Heart Lung Transplant. 2007;26(4):407–10.PubMedCrossRefGoogle Scholar
  84. 84.
    Brugiere O, Forget E, Biondi G, et al. Coccidioidomycosis in a lung transplant recipient acquired from the donor graft in France. Transplantation. 2009;88(11):1319–20.PubMedCrossRefGoogle Scholar
  85. 85.
    Wright PW, Pappagianis D, Wilson M, et al. Donor-related coccidioidomycosis in organ transplant recipients. Clin Infect Dis. 2003;37(9):1265–9.PubMedCrossRefGoogle Scholar
  86. 86.
    Proia L, Miller R. Endemic fungal infections in solid organ transplant recipients. Am J Transplant. 2009;9 Suppl 4:S199–207.PubMedCrossRefGoogle Scholar
  87. 87.
    Blair JE. Coccidioidomycosis in patients who have undergone transplantation. Ann NY Acad Sci. 2007;1111:365–76.PubMedCrossRefGoogle Scholar
  88. 88.
    Vikram HR, Blair JE. Coccidioidomycosis in transplant recipients: a primer for clinicians in nonendemic areas. Curr Opin Organ Transplant. 2009;14(6): 606–12.PubMedCrossRefGoogle Scholar
  89. 89.
    Blair JE. Approach to the solid organ transplant patient with latent infection and disease caused by Coccidioides species. Curr Opin Infect Dis. 2008;21(4):415–20.PubMedCrossRefGoogle Scholar
  90. 90.
    Baddley JW, Schain DC, Gupte AA, et al. Transmission of Cryptococcus neoformans by organ transplantation. Clin Infect Dis. 2011;52(4):e94–98.PubMedCrossRefGoogle Scholar
  91. 91.
    Kanj SS, Welty-Wolf K, Madden J, et al. Fungal infections in lung and heart-lung transplant recipients. Report of 9 cases and review of the literature. Medicine (Baltimore). 1996;75(3):142–56.Google Scholar
  92. 92.
    Sun HY, Alexander BD, Lortholary O, et al. Unrecognized pretransplant and donor-derived cryptococcal disease in organ transplant recipients. Clin Infect Dis. 2010;51(9):1062–9.PubMedCrossRefGoogle Scholar
  93. 93.
    Osawa R, Alexander BD, Forrest GN, et al. Geographic differences in disease expression of cryptococcosis in solid organ transplant recipients in the United States. Ann Transplant. 2010;15(4):77–83.PubMedGoogle Scholar
  94. 94.
    Osawa R, Alexander BD, Lortholary O, et al. Identifying predictors of central nervous system disease in solid organ transplant recipients with cryptococcosis. Transplantation. 2010;89(1):69–74.PubMedCrossRefGoogle Scholar
  95. 95.
    Sifri CD, Sun HY, Cacciarelli TV, Wispelwey B, Pruett TL, Singh N. Pretransplant cryptococcosis and outcome after liver transplantation. Liver Transpl. 2010;16(4):499–502.PubMedGoogle Scholar
  96. 96.
    Albano L, Bretagne S, Mamzer-Bruneel MF, et al. Evidence that graft-site candidiasis after kidney transplantation is acquired during organ recovery: a multicenter study in France. Clin Infect Dis. 2009;48(2): 194–202.PubMedCrossRefGoogle Scholar
  97. 97.
    Laouad I, Buchler M, Noel C, et al. Renal artery aneurysm secondary to Candida albicans in four kidney allograft recipients. Transplant Proc. 2005;37(6): 2834–6.PubMedCrossRefGoogle Scholar
  98. 98.
    Ferraz AS, Figueiredo JF. Transmission of Chagas’ disease through transplanted kidney: occurrence of the acute form of the disease in two recipients from the same donor. Rev Inst Med Trop Sao Paulo. 1993;35(5):461–3.PubMedCrossRefGoogle Scholar
  99. 99.
    de Faria JB, Alves G. Transmission of Chagas’ disease through cadaveric renal transplantation. Transplantation. 1993;56(6):1583–4.PubMedGoogle Scholar
  100. 100.
    Figueiredo JF, Martinez R, da Costa JC, Moyses Neto M, Suaid HJ, Ferraz AS. Transmission of Chagas disease through renal transplantation: report of a case. Trans R Soc Trop Med Hyg. 1990; 84(1):61–2.PubMedCrossRefGoogle Scholar
  101. 101.
    Souza FF, Castro ESO, Marin Neto JA, et al. Acute chagasic myocardiopathy after orthotopic liver transplantation with donor and recipient serologically negative for Trypanosoma cruzi: a case report. Transplant Proc. 2008;40(3):875–8.PubMedCrossRefGoogle Scholar
  102. 102.
    Rodriguez-Hernandez MJ, Ruiz-Perez-Pipaon M, Canas E, Bernal C, Gavilan F. Strongyloides stercoralis hyperinfection transmitted by liver allograft in a transplant recipient. Am J Transplant. 2009; 9(11):2637–40.PubMedCrossRefGoogle Scholar
  103. 103.
    Hoare M, Gelson WT, Davies SE, Curran M, Alexander GJ. Hepatic and intestinal schistosomiasis after orthotopic liver transplant. Liver Transpl. 2005;11(12):1603–7.PubMedCrossRefGoogle Scholar
  104. 104.
    Seth AK, Puri P, Chandra A, Dutta V, Naidu S, Saha A. Mixed Plasmodium falciparum and Plasmodium vivax malaria in orthotopic liver transplant recipient. Transplantation. 2009;88(2):288.Google Scholar
  105. 105.
    Notes from the field: transplant-transmitted Balamuthia mandrillaris—Arizona, 2010. MMWR Morb Mortal Wkly Rep. 2010;59(36):1182.Google Scholar
  106. 106.
    Balamuthia mandrillaris transmitted through organ transplantation—Mississippi, 2009. MMWR Morb Mortal Wkly Rep. 2010;59(36):1165–1170.Google Scholar
  107. 107.
    Rogers NM, Peh CA, Faull R, Pannell M, Cooper J, Russ GR. Transmission of toxoplasmosis in two renal allograft recipients receiving an organ from the same donor. Transpl Infect Dis. 2008;10(1):71–4.PubMedCrossRefGoogle Scholar
  108. 108.
    Renoult E, Biava MF, Hulin C, Frimat L, Hestin D, Kessler M. Transmission of toxoplasmosis by renal transplant: a report of four cases. Transplant Proc. 1996;28(1):181–3.PubMedGoogle Scholar
  109. 109.
    Mayes JT, O’Connor BJ, Avery R, Castellani W, Carey W. Transmission of Toxoplasma gondii infection by liver transplantation. Clin Infect Dis. 1995;21(3):511–5.PubMedCrossRefGoogle Scholar
  110. 110.
    Schwartz BS, Paster M, Ison MG, Chin-Hong PV. Organ donor screening practices for Trypanosoma cruzi infection among US organ procurement organizations. Am J Transplant. 2011;11(4):848–51.PubMedCrossRefGoogle Scholar
  111. 111.
    Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis. 2009;49(5):e52–54.PubMedCrossRefGoogle Scholar
  112. 112.
    Riarte A, Luna C, Sabatiello R, et al. Chagas’ disease in patients with kidney transplants: 7 years of experience 1989–1996. Clin Infect Dis. 1999;29(3):561–7.PubMedCrossRefGoogle Scholar
  113. 113.
    de Arteaga J, Massari PU, Galli B, Garzon Maceda F, Zlocowsky JC. Renal transplantation and Chagas’ disease. Transplant Proc. 1992;24(5):1900–1.PubMedGoogle Scholar
  114. 114.
    Hamilton KW, Abt PL, Rosenbach MA, et al. Donor-derived strongyloides stercoralis infections in renal transplant recipients. Transplantation. 2011;91(9):1019–24.PubMedCrossRefGoogle Scholar
  115. 115.
    Roxby AC, Gottlieb GS, Limaye AP. Strongyloidiasis in transplant patients. Clin Infect Dis. 2009;49(9): 1411–23.PubMedCrossRefGoogle Scholar
  116. 116.
    Vilela EG, Clemente WT, Mira RR, et al. Strongyloides stercoralis hyperinfection syndrome after liver transplantation: case report and literature review. Transpl Infect Dis. 2009;11(2):132–6.PubMedCrossRefGoogle Scholar
  117. 117.
    Ben-Youssef R, Baron P, Edson F, Raghavan R, Okechukwu O. Stronglyoides stercoralis infection from pancreas allograft: case report. Transplantation. 2005;80(7):997–8.PubMedCrossRefGoogle Scholar
  118. 118.
    Prusiner SB. Shattuck lecture—neurodegenerative diseases and prions. N Engl J Med. 2001;344(20): 1516–26.PubMedCrossRefGoogle Scholar
  119. 119.
    Ramasamy I, Law M, Collins S, Brooke F. Organ distribution of prion proteins in variant Creutzfeldt-Jakob disease. Lancet Infect Dis. 2003;3(4):214–22.PubMedCrossRefGoogle Scholar
  120. 120.
    Pauli G. Tissue safety in view of CJD and variant CJD. Cell Tissue Bank. 2005;6(3):191–200.PubMedCrossRefGoogle Scholar
  121. 121.
    Creange A, Gray F, Cesaro P, et al. Creutzfeldt-Jakob disease after liver transplantation. Ann Neurol. 1995;38(2):269–72.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.The Ohio State University College of MedicineColumbusUSA
  2. 2.Divisions of Infectious Diseases and Organ, TransplantationNorthwestern University Feinberg School of MedicineChicagoUSA

Personalised recommendations